| Compound Code | KAT-SED-02 |
| Pharmacological Tag | Sedative antihistamine / Anticholinergic / Hypnotic |
| Structural Class | Ethanolamine H1 receptor inreverse agonist |
| Mechanism | H1 receptor inverse agonist Central histamine suppression Muscarinic receptor blockade (anticholinergic load) Mild serotonergic modulation (non-primary) |
| Functional Role | Sleep induction Antiemetic (in combination with Vitamin B1) |
| Structural Analogues | Diphenhydramine Promethazine Carbinoxamine Other first-generation ethanolamines |
| Onset | ~30 minutes (oral) |
| Duration | 6–10 hours |
| Affinity Profile | High CNS penetration Strong H1 antagonism Moderate muscarinic antagonism Minimal selective receptor precision (dirty drug) |
| Pharmacokinetics | Oral bioavailability: high Peak plasma: 2-3h Half-life: ~10-12h Hepatic metabolism Renal elimination |
| Secondary effects | Somnolence Dry mouth Blurred vision Cognitive slowing Paradoxical excitation |
| Interpretation | Pre-receptor era sedative architecture Histamine shutdown in behavioural control Anticholinergic as therapeutic relevant Legacy molecule still in use on modern insomnia |